Company

Taigen Biotechnology

Taigen Biotechnology develops pharmaceutical products, including drugs for anti-infective diseases.

About

Founded in 2001, Taigen Biotechnology develops drugs for anti-infective diseases, including TG-1000, Burixafor, NEMONOXACIN, and Flarevir. It is based in Taipei, Taiwan - China, and has a branch office in Beijing. The company raised USD 37 million in Series C funding in January 2009, led by MPM Capital, with Taiwan Sugar Corporation and YFY Global Investment (BVI) also participating. Guolong Huang is the CEO.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in